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GenePreeclampsia is characterised by new onset hypertension and proteinuria and is a major obstetrical problem
for both mother and foetus. Haemolysis elevated liver enzymes and low platelets (HELLP) syndrome is an ob-
stetrical emergency and most cases occur in the presence of preeclampsia. Preeclampsia and HELLP are com-
plicated syndromes with a wide variety in severity of clinical symptoms and gestational age at onset. The
pathophysiology depends not only on periconceptional conditions and the foetal and placental genotype, but
also on the capability of thematernal system to deal with pregnancy. Genetically, preeclampsia is a complex dis-
order and despite numerous efforts no clearmode of inheritance has been established. Aminor fraction of HELLP
cases is caused by foetal homozygous LCHAD deﬁciency, but for most cases the genetic background has not been
elucidated yet. At least 178 genes have been described in relation to preeclampsia or HELLP syndrome. Conﬁned
placental mosaicism (CPM) is documented to cause early onset preeclampsia in some cases; the overall contri-
bution of CPM to the occurrence of preeclampsia has not been adequately investigated yet. This article is part
of a Special Issue entitled: Molecular Genetics of Human Reproductive Failure.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
1.1. Preeclampsia and HELLP syndrome: clinical spectrum
Preeclampsia is a pregnancy speciﬁc heterogenic multisystem dis-
order characterised by de novo hypertension (two blood pressure
measurements ≥140/90 mm Hg, more than 4 h apart) and protein-
uria (>300 mg/24 h) that develops after 20 weeks of gestation in a
formerly normotensive woman [71].
Preeclampsia complicates about 1.5 to 6% of pregnancies depending
on the populations studied [13,84,97] and is a major cause of maternal
and perinatal morbidity and mortality. Various forms of maternal
organ failure in for example liver, kidney and brain (seizures) occur as
a result of systemic vascular damage. The only true therapeutic option
is delivery, but at an early gestational age this forms a risk for the new-
born. Premature delivery is a major risk factor for perinatal death and
morbidity [54,63]. Treatment in early preeclampsia is therefore symp-
tomatic and aimed at prolonging pregnancy and preventing severe
maternal complications as long as foetal condition allows. It consists
of blood pressure regulation, seizure prophylaxis and monitoring foetallar Genetics of Human Repro-
linic, Academic Medical Center,
msterdam, The Netherlands.
l rights reserved.condition. In severe, particularly early onset disease, the foetusmay suf-
fer from increasing nutritional insufﬁciency (resulting in intra uterine
growth restriction (IUGR)), neonatal asphyxia, leading even to foetal
death. Premature birth, either because of foetal distress or deteriorating
maternal disease can have life long neurological consequences [77]. The
frequency and severity of preeclampsia is substantially increased in
womenwithmulti-foetal gestation, diabetesmellitus or kidney disease.
Chronic hypertension is also a risk factor for the development of the
preeclamptic phenotype and is called superimposed preeclampsia, as
de-novo hypertension is a criterion for the diagnosis preeclampsia.
HELLP is the acronym for haemolysis, elevated liver enzymes and
low platelets. HELLP syndrome is considered a complication of gesta-
tional hypertensive disease and occurs in about 10–20% of women
with severe preeclampsia. However, 10–20% of cases occur in the ab-
sence of preeclampsia, suggesting that the genetic background of pre-
eclampsia and HELLP may differ in some patients [86].
It has been documented that with progression of pregnancy a sub-
stantial fraction of patients initially admitted to hospital with either
preeclampsia, HELLP or IUGR, will go on to develop the full triad pre-
eclampsia/IUGR/HELLP syndrome (Fig. 1) [30].1.2. Preeclampsia and HELLP syndrome: pathophysiology
The pathogenesis of preeclampsia and HELLP syndrome is com-
plex (Fig. 1) and has been subject to investigation for decades. Pre-
pregnancymaternal susceptibility [25] combined to couple- and paternal
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Fig. 1. Schematic representation of the events leading to the different hypertensive disorders of pregnancy. The IUGR/HELLP/Preeclampsia ﬁgure on the bottom is adapted from
Ganzevoort et al. [30]. DM: diabetes mellitus. SLE: systemic lupus erythematodes. APLS: anti-phospholipid syndrome.
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tween the developing placenta and the maternal endometrium.
There are several key mechanisms involved that eventually lead to
the clinical syndrome of preeclampsia; the immune response at the
placental–maternal interface, superﬁcial placentation with insufﬁ-
cient remodelling of spiral arteries, an imbalance in angiogenic fac-
tors and oxidative stress that triggers inﬂammation. The resulting
insufﬁcient placental function combined with release of placental fac-
tors into the maternal circulation coupled to an exaggerated maternal
inﬂammatory response causes a generalized endothelial dysfunction
and leukocyte-, complement- and clotting activation [38,69,86]. This
results in the clinical syndrome of preeclampsia and HELLP syndrome
(Fig. 1).
1.2.1. Immunology
As the embryo expresses paternal antigens foreign to the mother's
immune system active regulation of the maternal immune response
at the placental–maternal interface is essential for a sustainable preg-
nancy [32,69].
The polymorphic HLA-C is expressed by invasive extravillous tro-
phoblasts. HLA-C is the dominant ligand for killer immunoglobulin-
like receptors (KIR) that are expressed bymaternal uterine natural killer
(uNK) cells. The KIR system contains two different haplotypes A and B
and someKIR/HLA-C combinations are presumed to bemore favourable
to trophoblast-cell invasion. Due to these two polymorphic gene sys-
tems at the site of placentation, uterine NK-cell function may vary
from pregnancy to pregnancy [34,62]. This immunological interfaceregresses in the second half of pregnancy when the villous syncytium
that is devoid of HLA expression becomes dominant [11,69].
The importance of an adequate immune regulation at the placental–
maternal interface is illustrated by the fact that abundant exposure to pa-
ternal antigens in seminal ﬂuids prior to the actual pregnancy seems to
prevent preeclampsia indicating some kind of ‘immunological memory’,
most likely by maternal T-cells [47,72,73]. Additionally the assisted re-
productive technique of oocyte donation with a high degree of antigenic
dissimilarity infers an increased risk of developing pregnancy-induced
hypertension [64,93].
1.2.2. Placentation and angiogenesis
Invasive cytotrophoblasts penetrate the walls of the spiral arteries
where they replace maternal endothelium, stimulating remodelling
of the arterial wall resulting in arterial dilatation [65]. The process
of extravillous cytotrophoblasts invasion into the spiral arteries is accom-
panied by an ‘epithelial to endothelial’ transition involving angiogenic
factors, their receptors and factors that regulate capillary function [104].
Several of these factors have been implicated in the pathogenesis of pre-
eclampsia, like, PlGF and VEGF-A, (soluble) FLT1, TGF-beta and (soluble)
Endoglin [56,96,104].
1.2.3. Oxidative stress and inﬂammation
The restricted invasion of cytotrophoblasts with impaired arterial
remodelling of the spiral arteries results in entering of maternal
blood into the intervillous space at higher pressure and faster rate.
This exposes the placental villi to ﬂuctuating oxygen concentrations
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injuries results in widespread placental lipid and protein oxidative
modiﬁcations that are pro-inﬂammatory. It also results in mitochon-
drial and endoplasmic reticulum stress, tissue apoptosis and necrosis.
Additionally, oxidative stress activates NF-κB a transcription factor
central to the inﬂammatory response and a cellular sensor of stress
[2,67]. This sequence of events links oxidative stress to inﬂammation.
The increase of necrotic trophoblast shedding due to oxidative stress
mechanisms [18] may be important in the pathogenesis of preeclampsia
in two ways; phagocytosis of necrotic trophoblasts results in systemic
endothelial cell activation via the secretion of interleukin 6 (IL-6) [16].
Secondly, the increased amount of microparticles derived from placental
syncytiotrophoblast in plasma samples from preeclamptic women are
able to interact with leucocytes and monocytes and can stimulate the
production of pro-inﬂammatory cytokines [94].2. Preeclampsia and HELLP syndrome: the underlying genetic basis
Supplementary Table 1 lists the 178 genes, miRNAs and proteins
reported in relation to preeclampsia or HELLP syndrome identiﬁed
by a PubMed search Gene[title/abstract] AND preeclampsia[MESH]
in the period 1989 till September 2011. The PANTHER (Protein ANal-
ysis THrough Evolutionary Relationships) database (www.pantherdb.
org) [89] was queried for the biological process relating to each gene.
Of the 178 genes listed, 110 are annotated to multiple processes, 37 to
only one biological process of which 22 link to a metabolic process. Of
31 genes no accompanying biological process was available, among
them 12 microRNA encoding genes (MIRs). Fig. 2 is a graphical dis-
play of the relative contribution of the biological processes according
to the PANTHER gene ontology database after exclusion of MIRs. The
most predominant biological processes are metabolic process (m-pro),
cell communication (com), immune process (imm) and response to
stimuli (resp) with respectively 17, 16, 13 and 10%. The chromosomal
localisation of each gene was retrieved using the NCBI data base and is
schematically depicted in Fig. 3. It reveals some ‘high density regions’
with several genes implicated in preeclampsia in close vicinity to each
other on chromosomes 6p, 9q, 11p and 19q. The genes displayed in
this table are a mixture of genes investigated with respect to mutations
or SNPs (e.g. HLA-C, FV, STOX1) and genes investigated with respect to
the level of expression (e.g. FLT1, ENG).3%
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Fig. 2. Biological processes assigned to the genes reported in relation to PE/HELLP presente
according to the PANTHER gene ontology database.2.1. Mode of inheritance, linkage analysis and the relative contribution of
genetic factors.
Over the years, the mode of inheritance of preeclampsia has been
a matter of debate. In the 1960's through 1980's an autosomal reces-
sive mode of inheritance was suggested, with either the maternal ge-
notype or the foetal genotype responsible for the maternal phenotype
of severe preeclampsia [17,21].
In the early 90's it was reported that homozygosity for a single re-
cessive gene in both mother and foetus would ﬁt 3–6% frequency of
preeclampsia in the general population [58]. In the 90's a large Icelan-
dic study concluded that either a recessive or a dominant model could
ﬁt [4]. As in preeclampsia familial clustering is not uncommon this of-
fers the possibility to apply genome wide linkage analysis where sus-
ceptibility loci and putative candidate genes can be identiﬁed. This
has been done in several studies for different populations (Table 1).
Linkage analysis is an example of an approach that does not assume
a speciﬁc underlying aetiology but expects a similar genotype in similarly
affected patients. Linkage analysis is the ideal genome-wide method for
mapping rare variants with relatively large effect sizes, but needs large
families to reach statistically signiﬁcant likelihood of disease (LOD)
scores. Table 1 summarises the results from the PubMed search Suscep-
tibility loci AND Preeclampsia. It shows an overview of the reported sus-
ceptibility loci and the candidate genes that could be involved in the
pathogenesis of preeclampsia or HELLP syndrome found with linkage
analysis. The largest sample size used to determine susceptibility loci in
preeclampsia research has been 343 women (Table 1) [5] and a study
this size is only able to identify genes with relatively large effects. Larger
samples sizes should be able to further elucidate the genetic background
of preeclampsia. Evolving insights might identify factors upstream in
pathways associated with the pathophysiology.
In 2001 a genome wide scan in 38 Dutch preeclampsia families re-
vealed a locus on 10q22 subject to a parent-of-origin effect [53]. Further
investigations of the families resulted in the identiﬁcation of a mater-
nally inherited mutation in exon 2 of the STOX1 gene that leads to an
amino acid substitution (Y153H). This gene lies adjacent but outside
the reported critical region of the originally described locus on 10q22.
They described that this STOX1 amino acid variation co-segregated
with the preeclampsia phenotype in seven of the eight families [95].
The epigenetic mechanism underlying this linkage was originally de-
scribed as being methylation induced silencing of the paternal allele%
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Fig. 3. Overview of chromosomal localisations of all genes reported in association with preeclampsia. Green lines represent genes retrieved by PubMed search. Red lines represent
search results overlapping with susceptibility loci reported based on the analysis of chorionic villous biopsy samples from patients destined to develop preeclampsia [29]. Blue lines
depict genes overlapping with susceptibility loci described in Table 1. Pink lines represent genes associated with HELLP syndrome. Conﬁned placental mosaicism of chromosomes
13 and 16 has been reported as having an increased risk of preeclampsia (ﬁgure modiﬁed from Sasaki et al. [79]).
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others have shown that STOX1 is not imprinted and that both themater-
nal and the paternal allele are expressed in human placenta of both nor-
motensive and preeclamptic pregnancies [37,49]. There is also no
evidence for the preferential transmission of the Y153H variation from
women with preeclampsia or IUGR to their offspring [8]. Despite dedi-
cated efforts to elucidate the molecular role of STOX1 in placenta and
preeclamptic placenta in particular, it remains elusive.
There is an association between preeclampsia/HELLP syndrome in
mothers with a child with Beckwith–Wiedemann syndrome and a
mutation on the maternal CDKN1C allele [75]. CDKN1C (alias p57KIP2)
is a regulator of cell cycle control [55] and paternally imprinted [12].
Deﬁciency of p57kip2 expression in mice induces preeclampsia-like
symptoms during pregnancy [44]. There is another example of a clear
Mendelian recessive mode of inheritance in case of HELLP syndrome
without preeclampsia. In pregnancies of foetuses homozygous for
the Glu474Gln Long-chain 3-hydroxacyl-coenzyme A dehydroge-
nase (LCHAD) mutation, 77% of the heterozygous mothers develop
severe pregnancy complications; acute fatty liver of pregnancy
(AFLP) in 54% ofmothers andHELLP syndrome in 23% [36,99]. However,
LCHAD deﬁciency only accounts for a small percentage of HELLP cases
and the genetic aetiology of HELLP syndrome remains to be unravelled
[24].
Overall, there is no compelling evidence to in general regard pre-
eclampsia as a Mendelian inherited disease and preeclampsia is cur-
rently mostly described as a ‘complex disorder’ meaning that it isbelieved to be associated with genetic changes combined with envi-
ronmental factors [4,15]. The diversity of biological processes to
which the genes in Supplementary Table 1 have been annotated and
the fact that only 25% of genes are annotated to a single biological
process substantiates the complex genetic background of the disease.
Different approaches have been used to determine the relative
contribution of genetic factors to preeclampsia. Twin studies help to
distinguish between environmental and genetic inﬂuences on indi-
vidual traits and behaviours. Two large twin studies on preeclampsia
have been reported but the data are conﬂicting. In a Swedish study
with 917 monozygotic and 1199 dizygotic twin pairs, the estimates
of heritability and non-shared environmental effect for preeclampsia
were 0.54 (95% CI 0–0.71) and 0.46 (95% CI 0.29–0.67) respectively
[78]. An Australian cohort study of in total 2362 female twin pairs in-
cluding only the most severe preeclamptic patients found no concor-
dant affected twin pairs [91].
To adjust for the possible genetic or environmental contributions
induced by parents, pregnancy outcomes in Swedish families over a
period of 11 years were analysed using their national birth register.
Information on 244,564 sib pairs with a total of 701,488 pregnancies
was available. They reported that 35% of the variance in risk of pre-
eclampsia was attributable to maternal genetic effects, 20% to foetal
genetic effects (with equal contribution ofmaternal and paternal genet-
ic effects), 13% to the liability of a speciﬁc couple, which is assumed to
be the same in all successive pregnancies in the same couple, less than
1% to shared sib environment, and 32% to undetermined factors [19].
Table 1
Reported susceptibility loci for preeclampsia. Candidate genes in bold were conﬁrmed by Founds S.A. et al. [28] by comparing susceptibility loci with gene expression data obtained from microarray analysis of chorionic villous sampling
(CVS) from women whose pregnancies were complicated by preeclampsia.
Locus Candidate gene LOD-score/
NPL-score
Technique Population Nr of cases Clinical deﬁnition PE Author
Blood pressure/laboratory results Proteinuria
4q RUFY3 2.9L Genome wide linkage study Australian 15 pedigrees SPEa: BPb>140/90 mm Hg
MPEc: BP>140/90 without proteinuria
>0.3 g/l protein in 24 h Harrison et al. 1997
2p13 EPAS 4.7L Genome wide screen Icelandic 343 General criteria: GHd, PE or E
Strict criteria: PE or E
Arngrimsson et al. 1999
7q36 NOS3/SEMA3C 2.143L Genome wide linkage study Australian 26 families MPE: BP>140/90 mm Hg
SPE: BP>140/90 mm Hg
E: all above mentioned with seizures
MPE: no proteinuria
SPE: >0.3 g/l protein in 24 h
Guo et al.1999
2p12
11q23-q24
2q23
EPAS
MMP12
FN1/ACVR2
2.58L
2.02L
3.43L
Medium density
genome scan
Australian/New Zealand 121 women MPE: BP>140/90 mm Hg
SPE: BP>140/90 mm Hg
E: all above mentioned with seizures
MPE: no proteinuria
SPE: >0.3 g/l protein in 24 h
Moses et al. 2000
Fitzpatrick et al. 2004
12q
22q13.1
10q22.1
11q13
SART3
STOX1
1.99L
2.41L
2.38L
Genome wide linkage study Dutch 67 sibpair families MPE: de novo hypertension
PE: BP>140/90 mm Hg
E: above mentioned complicated with
seizures HELLP: LDHc>600 IU/l and
ASATd and ALATe >70 IU/l
and b100 platelets*10^9/l
MPE: no proteinuria
PE: >0.3 g/l proteinuria
Lachmeijer et al. 2001
2p12-p13 EPAS P=0.04 Finnish 305 PE: BP>140/90 mm Hg PE: new onset proteinuria
of >300 mg
Laasanen et al. 2003
2p25
9p13
4q32
EPAS
TLR2
3.77 N
3.74 N
3.13 N
Genome wide screen Finnish 15 families MPE: BP>140/90 mm Hg
SPE: BP>160/110 mm Hg
E : all above mentioned with seizures
MPE: no proteinuria
SPE: >2 g/l protein in 24 h
Laivuori et al. 2003
3q11.1-21.2
7q34-7q36.3
9q34.1-9q34.3
2q37.1-2q37.3
HPS3
SEMA3C
PAEP
FN1
HEGESMAe MPE: BP>140/90 mm Hg
SPE: BP>140/90 mm Hg
E: all above mentioned with seizures
MPE: no proteinuria
SPE: >0.3 g/l protein in 24 h
Zintzaras et al. 2006
5q
13q
ELL2/ERAP
OXGR1
3.12L
3.10L
Medium density
genome scan
Australian/New Zealand 34 families MPE: BP>140/90 mm Hg
SPE: BP>140/90 mm Hg
PE: all above mentioned with seizures
MPE: no proteinuria
SPE: >0.3 g/l protein in 24 h
Johnson et al. 2007
L=LOD-score (LOD scores of 0.59, 1.17 and 2.07 correspond to signiﬁcance levels of b0.05, b0.01 and b0.001 respectively), N=NPL-score (NPL scores of 1.65, 2.33 and 3.09 correspond to signiﬁcance levels of b0.05, b0.01 and b0.001
respectively) [51]. All clinical features stated appeared after 20 weeks of gestation.
a SPE=severe preeclampsia.
b MPE=mild preeclampsia.
c BP=bloodpressure.
d GH=gestational hypertension.
e HEGESMA=heterogeneity-based genome search meta-analysis.
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netic component [85]. In conclusion:most studies report that the genet-
ic contribution to the development of preeclampsia is around 50%
implying that gene–environment interactions play a role.
Both excess homocysteine and dietary deﬁciencies of folate and
vitamins B6 and B12 have been implicated in the pathogenesis of pre-
eclampsia, although results are not unequivocal [6,26,45,59]. The pro-
posed mechanism of hyperhomocysteinemia-induced pre-eclampsia
is that homocysteine can accumulate through either increased dietary
methionine or a deﬁciency of B vitamins and folate. Excess homocyste-
ine can then be converted to S-adenosyl homocysteine (SAH) through
the enzyme SAH hydrolase. High levels of SAH can inhibit catechol-
O-methyltransferase (COMT), an enzyme that metabolizes estradiols.
Decreased COMT activity can deplete levels of 2-ME, a metabolite of
COMT capable of regulatingHIF-1a levels. COMT deﬁciency is associated
with preeclampsia in mice [43].
Although the supplementation of vitamins C and E as anti-oxidants
to reduce oxidative stress and prevent preeclampsia seemed promising
at ﬁrst [14], randomized trials do not support a role for vitamins C and E
in preventing preeclampsia [20]. One trial even showed that vitamins C
and E increase the risk of foetal loss or perinatal death [102].
Although smoking during pregnancy may lead to many adverse
effects such as foetal growth restriction, placental abruption, stillbirth,
and preterm labour, smoking is the only environmental exposure
known to consistently reduce the risk of preeclampsia and gestational
hypertension [98]. The protective mechanism is still under research.2.2. Conﬁned placental mosaicism in relation to preeclampsia
With the exception of those involving chromosomes 13, 18 or 21
all trisomic pregnancies tend to undergo spontaneous abortions. So
when an ongoing pregnancy with for instance a trisomy 3 is diag-
nosed prenatally it is considered to be a conﬁned placental mosaicism
(CPM). The incidence of CPM in chorionic villous samples is 1–2%
[74]. Trisomy in placenta can affect cytotrophoblast differentiation,
which is a prerequisite for proper placentation [100]. Trisomy mainly
occurs due to non-disjunction events [41].
Based on the tissue of conﬁnement of trisomy, CPM is differentiated
into three types; CPM conﬁned to cytotrophoblasts (type I), conﬁned to
mesenchymal core (type II) and CPM present in both cytotrophoblasts
and mesenchymal core (type III) [90].
Type I is the most commonly occurring CPM subtype and no ad-
verse pregnancy outcomes have been reported. CPM type III occurs
less frequently, but is commonly associated with a poor pregnancy
outcome [74]. Type III CPM usually has an early meiotic origin of the
error (non-disjunction) giving rise to a trisomic embryo; subsequent
rescue of trisomy in progenitor cells of foetus leaves the placenta al-
most entirely trisomic (Fig. 4).
Some studies have reported that presence of a type III placental
trisomy can cause IUGR [74,90] or preeclampsia [3,9,74]. Especially
CPM of trisomy 13 has been reported as having an increased risk of
preeclampsia [7,9,33,50]. This might relate to the fact that the FLT1
gene is localized on 13q12.3. sFLT1 protein levels in maternal serum
of pregnancies with a trisomy 13 conﬁned to the placenta, were 35%
higher compared to normal pregnancies [7]. Additionally, in non-
pregnant rats the administration of sFLT1 evokes preeclampsia like
symptoms [60]. All evidence points to a gene-dosage effect of sFLT1
in preeclampsia. Placental trisomy 16 has also been reported in asso-
ciation with preeclampsia [10,42] with a 3–4 times increased risk of
preeclampsia compared to a control population [103]. The occurrence
of preeclampsia in 25 prenatally diagnosed mosaic trisomy 16 preg-
nancies was investigated and higher levels of trisomy were observed
in all placental lineages of preeclamptic cases when compared to the
non-preeclamptic cases. Uniparental disomy (UPD) did not seem to
inﬂuence the risk of pre-eclampsia in this study [103].Recently, the presence of placental trisomy by comparative genomic
hybridisation was investigated in 43 IUGR placentas (of which 25 were
associated with preeclampsia), 18 preeclamptic placentas and 11 pla-
centas with abnormal maternal serum ﬁndings in relation to trisomy
21 screening. Of these 72 placentas analysed, 6 placentas had placental
trisomy. Two out of six cases with placental trisomy had onset of pre-
eclampsia before the 34th week of gestation. In none of the 85 control
placentas placental CPM was observed [74]. Fig. 3 depicts that only a
few genes previously investigated in relation to preeclampsia are locat-
ed on chromosomes 13 and 16. Most genes associated with preeclamp-
sia, listed in Supplementary Table 1 located on chromosome 13 or 16
were indeed identiﬁed based on differential expression. Coagulation
factor 7(F7), located on 13q34, was identiﬁed based on investigations
on preeclampsia in women who delivered a trisomy 13 [92].
2.3. Identiﬁcation of candidate genes based on pathophysiology
Many investigators apply a hypothesis driven approach where
they investigate associations between the disease and changes in can-
didate genes implied in the pathogenesis.
2.3.1. Immunology
Some KIR/HLA-C combinations appear unfavourable to trophoblast-
cell invasion [61]. Mothers with an AA killer immunoglobulin-like re-
ceptors (KIR) genotype and a foetuswith a paternalHLA-C2 are at great-
ly increased risk of a preeclamptic pregnancy [34,69].
Additionally, genetic susceptibility of HLA-DR4 with preeclampsia
has been described [48].
2.3.2. Placentation and angiogenesis
The vascular endothelial growth factor (VEGF) ligands and their
receptors play an essential role in both normal and pathological func-
tioning of the endothelium [87]. VEGF receptor 1 (VEGFR1) also known
as FLT1 (Fms-like tyrosine kinase 1) is a transmembrane tyrosine kinase
type receptor with multiple ligands (Placental growth factor (PlGF),
VEGF-A and VEGF-B). Ultimately activation of these receptors plays a
key role in angiogenesis [76]. Apart from the transmembrane form of
VEGFR1, there is a soluble form lacking the transmembrane domain.
This soluble truncated version of VEGF receptor 1 (also known as sFLT1)
is markedly elevated in the circulation of preeclamptic women [60].
The current concept of the role of sFLT1 in preeclampsia is that it traps
its ligands VEGF and PlGF, thereby lowering free circulating levels of
these factors below a critical threshold. sFLT1 mRNA is generated by
alternative splicing of the FLT1gene. The discovery of additional alterna-
tive spliced FLT1 transcripts encoding novel soluble (s)FLT1 protein
isoforms [46,80,88] complicates both the predictive value and function-
al implications of sFLT1 in preeclampsia. Placenta has by far the highest
FLT1mRNA expression level compared to other tissues and expression is
directly up-regulated by hypoxia via a hypoxia-inducible enhancer ele-
ment in the FLT1 gene promoter [31]. Over 80% of placental transcripts
correspond to sFLT1_v2. Placental FLT1 transcript levels are increased
not only in preeclampsia but also in normotensive pregnancy with a
small for gestational age foetus. This may indicate a common pathway
involved in the development of both conditions [39]. Injection of sFLT1
expressing adenovirus in rats results in increased blood pressure
and proteinuria, but this is pregnancy independent [60]. A mouse
model with placenta-speciﬁc sFLT1 expression demonstrates hyper-
tension and proteinuria in pregnancy that resolve after delivery [52].
Endoglin is an auxiliary cell surface receptor for the transforming
growth factor beta 1(TGF-β1) and TGF-β3 that are potent inhibitors
of trophoblast differentiation and migration. Soluble endoglin, the
product of proteolytic cleavage of endoglin, inhibits the action of
TGF‐β1 and TGF-β3. The expression of ENG and the production of solu-
ble endoglin is upregulated in preeclamptic placenta. Elevated serum
soluble endoglin levels correlate with disease severity. Soluble endoglin
is able to produce increased vascular permeability and hypertension in
Fig. 4. CPM by meiotic non-disjunction and trisomy rescue in the foetus: a meiotic non-disjunction event in one of the parental gametes gives rise to a diploid gamete which sub-
sequently fuses with a normal gamete resulting in a trisomic embryo. In a later stage during post-zygotic divisions the progenitor cells of the foetus undergo trisomy rescue and lose
the extra chromosome. The foetus becomes diploid and as a result the trisomy is conﬁned to the placenta.
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in rats results even in amore severe preeclamptic phenotype combined
with HELLP [96]. The identity of the protein responsible for the increased
cleavage of endoglin and the production of the soluble form has recently
been attributed to MMP-14 [40]. Soluble endoglin is upregulated in pre-
eclampsia in a pattern similar to sFLT1 [83].
2.3.3. Oxidative stress and inﬂammation
In placenta, COMT metabolizes estradiols to 2-methoxy-estradiol,
an estradiol metabolite that destabilizes hypoxia-inducible factor
(HIF)-1a. HIF proteins mediate the effects of hypoxia on gene expres-
sion by up regulating transcription of target genes, including FLT1
with preference for the alternative splice product sFLT1. This role
of COMT in maintaining oxygen balance suggests that COMT might
somehow be involved in the pathogenesis of pre-eclampsia through
an altered response to oxidative stress [82]. Recently it has been
shown that homozygosity for the variant allele of the maternal
COMT gene may increase susceptibility to preeclampsia [57]. This is
further supported by the fact that compared to wild type mice,
comt−/−mice have increased blood pressures, higher levels of protein-
uria, smaller offspring and smaller placenta's [43]. COMT has also been
shown to interact with methylenetetrahydrofolate reductase (MTHFR),
which modulates the availability of S-adenosylmethionine (SAM), a
COMT cofactor. Variations in both foetal and maternal MTHFR have
been associated with preeclampsia [35]. In addition some mothers
and foetus are more susceptible to oxidative stress compared to others
due to impaired function in scavenger molecules like glutathione
S-transferases (GTS) P1, M1 and T1, epoxide hydrolase (EPHX) and cy-
tochrome P4501A1 (CYP1A1) [105].
Inﬂammatory cytokines like TNF-alpha, IL-6 and IL-10 have been im-
plicated to contribute to the pathological inﬂammation process seen in
preeclampsia. In 2011 a systematic review of preeclampsia in relationto polymorphisms and circulating concentrations of these cytokines
reported that maternal TNF-a-308G/A, IL-6 174G/C and IL-10-1082A/G
polymorphisms were not associated with preeclampsia [101]. On the
other hand, maternal serum concentrations of all three cytokines were
signiﬁcantly higher in preeclampsia patients versus controls. These
ﬁndings strengthen the clinical evidence that preeclampsia is accom-
panied by an exaggerated inﬂammatory response, but do not support
TNF-α-308G/A, IL-6-174G/C, and IL-10-1082A/G as candidate suscepti-
bility loci in preeclampsia [101].
In 2006 it was reported that 7 genes (AGT, (angiotensinogen), AGTR1
and AGTR2 (the angiotensin receptors), FV (coagulation factor v),MTHFR
(methylenetetrahydrofolate reductase), NOS3 (nitric oxide synthase 3)
and TNF-α (tumour necrosis factor-alpha)) dominate 70% of literature
regarding the genetics of preeclampsia [15]. The interest in these genes
can be explained by their involvement in different underlying aetiologies
relevant to the pathogenesis of preeclampsia. Angiotensinogen and the
angiotensin receptors are part of the renin–angiotensin system that reg-
ulates blood pressure [23]. Transgenicmice overexpressing human renin
and angiotensinogen develop superimposed preeclampsia [27]. Factor V
is part of the blood coagulation pathway and severe and early-onset pre-
eclampsia is signiﬁcantly associated with inherited thrombophilia [66].
MTHFR plays a role in homocysteine metabolism [35]. NOS3 (also
known as endothelial NOS) is important in vasodilation required to
accommodate the increased circulating volume during pregnancy with-
out a rise in blood pressure [81] and TNF-alpha is an important apop-
tosis inducer [70]. The GOPEC consortium analysed these 7 candidate
genes reported as conferring susceptibility to preeclampsia in 627 UK
familieswith preeclampsia (including 398maternal triads and 536 foetal
triads). Using the transmission disequilibrium test, no genotype
risk ratio achieved the pre speciﬁed criteria for statistical signiﬁ-
cance [1].
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Since the discovery of DNA in the 1960's numerous efforts have
been made to elucidate the genetic background of preeclampsia;
alas without comprehensive results. Currently, there is no established
genotype–phenotype relation for preeclampsia. A pitfall in deﬁning
the mode of inheritance has been the spectrum of different subtypes
of women who all meet the ISSHP criteria [71] of de novo hyperten-
sion and proteinuria.
The most likely reason is that we are dealing with a complex disor-
der; preeclampsia and HELLP are complicated syndromes with a very
wide range of clinical symptoms depending not only onpericonceptional
conditions and the foetal and placental genotype, but also on the capa-
bility of the maternal system to deal with the reproductive challenge
that pregnancy is. For HELLP syndrome one example of a genotype–
phenotype correlation exist; heterozygotic women carrying a LCHAD
deﬁcient foetus have a 77% risk of AFLP or HELLP syndrome.
At present there are very few studies that have investigated the
presence of placental aneuploidy in preeclamptic cases and therefore
it is difﬁcult to give an appropriate risk estimate based on the avail-
able data. Prenatally diagnosed trisomy 13 and trisomy 16 have an in-
creased risk of pre-eclampsia when compared to the other trisomies
and should be provided better obstetrical supervision.
Data from micro-array and SAGE analysis report genes with altered
expression in preeclampsia/HELLP placenta. Theoretically the cause for
this altered expression can bewithin the causative gene, in an upstream
factor inﬂuencing transcription, or in a downstream factor inﬂuencing
mRNA stability. With the exemption of HIF-1a the data coming from
the diverse molecular studies have not been fully integrated yet.
4. Current challenges and future perspectives
The ISSHP criteria for preeclampsia are generally accepted across
the world. The next step should be to reach international consensus
on criteria for the different sub-types of preeclampsia varying from
mild hypertension and some proteinuria at term to severe hyperten-
sion, proteinuria, eclampsia and additional laboratory abnormalities
at an early gestational age. Factors like predisposing maternal factors,
a positive family history of preeclampsia, early onset disease and the
combination with either IUGR and/or HELLP syndrome should be
taken into account to investigate causative factors in homogenous
subgroups of women who all meet the ISSHP criteria of preeclampsia.
International collaboration is essential to reach adequate power to
detect the molecular cause of speciﬁc sub-types. Basic research based
on pathophysiological mechanisms will be essential to provide insights
and tell us whether previous ﬁndings are cause or consequence.
More research is needed to determine the true incidence of CPM in re-
lation to preeclampsia. Given undisputed involvement of sFLT1 in the
aetiology of preeclampsia, the location of the FLT1 gene on chromosome
13 and the consistent evidence of raised levels of sFLT1 in preeclamptic
women this is worth pursuing.
Ultimately, theﬁrmestablishment of the genetic basis of preeclamp-
sia and HELLP syndrome will provide a rational basis for the develop-
ment of further prognostic and therapeutic targets.
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